Mella O - Search Results

1

[Should complementary therapies be offered in hospitals?].

Risberg T, Bremnes Y, Kolstad A, Holte H, Wist E, Mella O, Klepp O. Risberg T, et al. Among authors: mella o. Tidsskr Nor Laegeforen. 2004 Dec 2;124(23):3078-80. Tidsskr Nor Laegeforen. 2004. PMID: 15586193 Free article. Norwegian.

2

[Should alternative therapists treat cancer--what is the opinion of oncology health personnel?].

Risberg T, Kolstad A, Wist EA, Holte H, Mella O, Klepp O. Risberg T, et al. Among authors: mella o. Tidsskr Nor Laegeforen. 2003 Nov 6;123(21):3059-61. Tidsskr Nor Laegeforen. 2003. PMID: 14618177 Free article. Norwegian.

3

Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway.

Kolstad A, Risberg T, Bremnes Y, Wilsgaard T, Holte H, Klepp O, Mella O, Wist E. Kolstad A, et al. Among authors: mella o. Support Care Cancer. 2004 May;12(5):312-8. doi: 10.1007/s00520-004-0590-9. Epub 2004 Feb 6. Support Care Cancer. 2004. PMID: 14767750

4

Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway.

Risberg T, Kolstad A, Bremnes Y, Holte H, Wist EA, Mella O, Klepp O, Wilsgaard T, Cassileth BR. Risberg T, et al. Among authors: mella o. Eur J Cancer. 2004 Mar;40(4):529-35. doi: 10.1016/j.ejca.2003.11.011. Eur J Cancer. 2004. PMID: 14962719

5

[High dose therapy with autologous stem cell support in malignant disorders. Excerpt from the statement by the advisory group of the State Health Services].

Holte H, Kvaløy SO, Engan T, Evensen SA, Mella O, Tangen JM, Wesenberg F, Wist EA. Holte H, et al. Among authors: mella o. Tidsskr Nor Laegeforen. 1996 Sep 10;116(21):2577-81. Tidsskr Nor Laegeforen. 1996. PMID: 8928130 Norwegian.

6

[Levonantradol as an antiemetic in cancer chemotherapy].

Mella O, Følling Elgjo R, Isaksen H, Klepp O. Mella O, et al. Tidsskr Nor Laegeforen. 1984 Nov 30;104(33):2320-2. Tidsskr Nor Laegeforen. 1984. PMID: 6523465 Norwegian. No abstract available.

7

ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's disease.

Holte H, Mella O, Wist E, Telhaug R, Hannisdal E, Abrahamsen AF. Holte H, et al. Among authors: mella o. Acta Oncol. 1996;35 Suppl 8:73-80. doi: 10.3109/02841869609098523. Acta Oncol. 1996. PMID: 9073051 Clinical Trial.

8

Droloxifene--a new anti-estrogen. A phase II study in advanced breast cancer.

Haarstad H, Gundersen S, Wist E, Raabe N, Mella O, Kvinnsland S. Haarstad H, et al. Among authors: mella o. Acta Oncol. 1992;31(4):425-8. doi: 10.3109/02841869209088284. Acta Oncol. 1992. PMID: 1632978 Clinical Trial.

9

[Home care for patients with terminal cancer. 1 year's material from Bergen].

Mella O, Lønning PE, Aaserud E. Mella O, et al. Tidsskr Nor Laegeforen. 1987 May 30;107(15):1361-3. Tidsskr Nor Laegeforen. 1987. PMID: 3603506 Norwegian. No abstract available.

10

Norwegian oncologists' expectations of intensity-modulated radiotherapy.

Muren LP, Mella O, Hafslund R, Dahl O. Muren LP, et al. Among authors: mella o. Acta Oncol. 2002;41(6):562-5. doi: 10.1080/02841860214967. Acta Oncol. 2002. PMID: 12546530

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters